CERo Therapeutics Announces $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
SOUTH SAN FRANSCISCO, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) — CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation